On March 13th 2026 MAPS received notice that the NIDA Drug Supply Program (NDSP) – which provides qualified researchers with free or low-cost controlled substances, research chemicals, and cannabis products for pre-clinical and clinical studies – approved MAPS’ request for 9,707.1 grams of placebo cannabis for use in the MJP2 Phase 2 clinical trial of inhaled cannabis in the treatment of PTSD in U.S. military veterans.